Engineering systems to monitor and understand cancer cell diversity
Official title: IMAT-ITCR Collaboration: Engineering model-based systems to monitor and steer subclonal dynamics
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11137295 · Data updated 2026-11-12
This study is looking at how different types of cancer cells change and grow over time, using advanced technology to help understand your specific cancer better, which could lead to more tailored treatments just for you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $75,785 |
| NIH project number | 3R21CA269415-02S1 |
| Project ID | NIH-11137295 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with various types of cancer who exhibit genetic mutations and subclonal diversity.
✕Less likely to help
Patients with early-stage cancers that do not exhibit significant genetic diversity may not benefit from this research.
What this research studies
This research focuses on understanding the complex genetic variations within cancer cells, particularly how different subclones of cancer cells behave and evolve. By integrating advanced genomic techniques and bioinformatics, the project aims to develop systems that can track and analyze these variations at a single-cell level. This approach utilizes CRISPR technology and single-cell RNA sequencing to model cancer mutations and monitor their effects over time. Patients may benefit from insights gained about their specific cancer subtypes, leading to more personalized treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and tailored cancer treatments by providing a deeper understanding of tumor heterogeneity.
How similar studies have gone: Previous research has shown promise in using CRISPR and single-cell sequencing to study cancer, indicating that this approach could yield valuable insights.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Andor, Noemi — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Andor, Noemi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.